EUCTR2014-003346-27-IT进行中（未招募）1 期
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy - na
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, between the ages of 16 and 25 years, inclusive, in Stage 1 and 12 and 15 years, inclusive, in Stage 2.
- •2. Established, genetically confirmed diagnosis of FSHD (Type 1 or 2).
- •3. Onset of FSHD signs or symptoms (e.g., facial weakness, scapular winging, weakness in upper or lower extremities) prior to 10 years of age, as documented in the patient's medical record or based on patient or family report.
- •4. Provide written informed consent or assent (as appropriate, based on age of majority).
- •5. In the Investigator's opinion, patient is willing and able to complete all study procedures and comply with the weekly study visit schedule
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Currently receiving treatment with an immunomodulatory agent or history of such treatment, including targeted biological therapies (e.g., etanercept, omalizumab) within the 3 months before baseline; corticosteroids within 3 months before baseline; or high-dose nonsteroidal
- •anti-inflammatory agents (NSAIDs; either chronic or intermittent) within 2 weeks before baseline.
- •2. Currently receiving curcumin or albuterol or requires such treatment during study participation; use of a product that putatively enhances muscle growth (e.g., insulin-like growth factor, growth hormone) or activity (e.g., Coenzyme Q, Coenzyme A, creatinine, L-carnitine) on a chronic basis within 4 weeks before baseline; statin treatment initiatio or significant adjustment to statin regimen within 3 months before baseline (stable, chronic statin use is permissible).
- •3. Use of an investigational product or device (other than a mobility assistance device) within 30 days before baseline.
- •4. Evidence of an alternative diagnosis other than FSHD or a co-existing myopathy or dystrophy, based on prior muscle biopsy or other available investigations.
- •5. History of severe restrictive or obstructive lung disease (including interstitial lung disease, pulmonary fibrosis, or asthma), or evidence for interstitial lung disease on screening chest radiograph.
- •6. History of anti-synthetase syndrome, prior Jo-1 Ab-positivity, or Jo 1 Ab level = 0.6 U/mL on screening.
- •7. Acute or clinically relevant Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection or re-activation.
- •8. Chronic infection, such as hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) or a history of tuberculosis.
- •9. Vaccination within 8 weeks before baseline or vaccination is planned during study participation.
- •10. Evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, dermatological, or gastrointestinal disease, cognitive impairment, or a condition that requires immediate surgical intervention or other treatment, or may not allow safe participation in the study.
- •11. Muscle biopsy within 30 days before baseline.
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular DystrophiesEUCTR2015-001910-88-DKaTyr Pharma, Inc.16
进行中（未招募）
不适用
A clinical study to evaluate the safety and preliminary efficacy of BPS804 in adults with hypophosphatasiaHypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal mineralization, and which is caused by the absence of or by deficient enzymatic activity of the tissue-nonspecific alkaline phosphatase (TNSALP)MedDRA version: 14.1Level: PTClassification code 10049933Term: HypophosphatasiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-024013-31-DEovartis Pharma Services AG9
进行中（未招募）
1 期
An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage)Primary Focal Segmental Glomerulosclerosis (FSGS)MedDRA version: 21.1Level: PTClassification code 10067757Term: Focal segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-003022-32-PLChemoCentryx, Inc.13
进行中（未招募）
1 期
A research study to look at the safety, effectiveness and the effects on the body of a new drug, SBC-102, in children with growth problems caused by a deficiency in the enzyme that breaks down fatsEUCTR2011-000032-28-GBSynageva Biopharma Corp.10
进行中（未招募）
1 期
A research study to look at the safety, effectiveness and the effects on the body of a new drug, SBC-102, in children with growth problems caused by a deficiency in the enzyme that breaks down fatsGrowth failure in children due to lysosomal acid lipase deficiency (Wolman disease).MedDRA version: 13.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: HLGTClassification code 10021605Term: Inborn errors of metabolismSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000032-28-FRSynageva Biopharma Corp.8